FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1855-1862 June 17, 1999 Number 24 Next

	Full Text PDF Editorial by Podrid, P. J. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Patients with implantable cardioverter–defibrillators often receive adjunctive antiarrhythmic therapy to prevent frequent shocks. We tested the efficacy and safety of sotalol, a beta-blocker with class III antiarrhythmic effects, for this purpose.

Methods In a multicenter trial, patients were stratified according to left ventricular ejection fraction (0.30 or >0.30), randomly assigned to double-blind treatment with 160 to 320 mg of sotalol per day (151 patients) or matching placebo (151 patients), and followed for 12 months. Kaplan–Meier analyses of the time to an event were performed. Three end points were used: the delivery of a first shock for any reason or death from any cause, the first appropriate shock for a ventricular arrhythmia or death from any cause, and the first inappropriate shock for a supraventricular arrhythmia or death from any cause.

Results Compliance with double-blind treatment was similar in the two groups. There were seven deaths in the placebo group and four in the sotalol group. As compared with placebo, treatment with sotalol was associated with a lower risk of death from any cause or the delivery of a first shock for any reason (reduction in risk, 48 percent; P<0.001 by the log-rank test), death from any cause or the delivery of a first appropriate shock (reduction in risk, 44 percent; P=0.007), or death from any cause or the delivery of a first inappropriate shock (reduction in risk, 64 percent; P=0.004). Sotalol also reduced the mean (±SD) frequency of shocks due to any cause (1.43± 3.53 shocks per year, as compared with 3.89±10.65 in the placebo group; P=0.008). In the sotalol group, the reduction in the risk of death from any cause or the delivery of a first shock for any reason did not differ significantly between patients with ejection fractions of more than 0.30 and those with ejection fractions of 0.30 or less.

Conclusions Oral sotalol was safe and efficacious in reducing the risk of death or the delivery of a first defibrillator shock whether or not ventricular function was depressed.

Source Information

From the Texas Arrhythmia Institute, Houston (A.P., P.D.H.); J.W. Goethe University, Frankfurt, Germany (S.H.H.); Berlex Laboratories, Montville, N.J. (J.H.W., B.T.), Eastern Heart Institute, Millburn, N.J. (S.S.); and St. Vincent Hospital, Indianapolis (E.N.P.).

Address reprint requests to Dr. Pacifico at the Texas Arrhythmia Institute, 6560 Fannin St., Suite 620, Houston, TX 77030, or at apacifico{at}tmh.tmc.edu.

Full Text of this Article

This article has been cited by other articles:

• Task force members, , Vijgen, J., Botto, G., Camm, J., Hoijer, C.-J., Jung, W., Le Heuzey, J.-Y., Lubinski, A., Norekval, T. M., Santomauro, M., Schalij, M., Schmid, J.-P., Vardas, P. (2009). Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators. Europace 0: eup112v1-eup112 [Abstract] [Full Text]  
• Aliot, E. M., Stevenson, W. G., Almendral-Garrote, J. M., Bogun, F., Calkins, C. H., Delacretaz, E., Bella, P. D., Hindricks, G., Jais, P., Josephson, M. E., Kautzner, J., Kay, G. N., Kuck, K.-H., Lerman, B. B., Marchlinski, F., Reddy, V., Schalij, M.-J., Schilling, R., Soejima, K., Wilber, D. (2009). EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Europace 11: 771-817 [Full Text]  
• Stevenson, W. G., Wilber, D. J., Natale, A., Jackman, W. M., Marchlinski, F. E., Talbert, T., Gonzalez, M. D., Worley, S. J., Daoud, E. G., Hwang, C., Schuger, C., Bump, T. E., Jazayeri, M., Tomassoni, G. F., Kopelman, H. A., Soejima, K., Nakagawa, H., for the Multicenter Thermocool VT Ablation Trial I, (2008). Irrigated Radiofrequency Catheter Ablation Guided by Electroanatomic Mapping for Recurrent Ventricular Tachycardia After Myocardial Infarction: The Multicenter Thermocool Ventricular Tachycardia Ablation Trial. Circulation 118: 2773-2782 [Abstract] [Full Text]  
• Dorian, P., Al-Khalidi, H. R., Hohnloser, S. H., Brum, J. M., Dunnmon, P. M., Pratt, C. M., Holroyde, M. J., Kowey, P., on behalf of the SHIELD (SHock Inhibition Evaluati, (2008). Azimilide Reduces Emergency Department Visits and Hospitalizations in Patients With an Implantable Cardioverter-Defibrillator in a Placebo-Controlled Clinical Trial. J Am Coll Cardiol 52: 1076-1083 [Abstract] [Full Text]  
• Daubert, J. P., Zareba, W., Cannom, D. S., McNitt, S., Rosero, S. Z., Wang, P., Schuger, C., Steinberg, J. S., Higgins, S. L., Wilber, D. J., Klein, H., Andrews, M. L., Hall, W. J., Moss, A. J., for the MADIT II Investigators, (2008). Inappropriate Implantable Cardioverter-Defibrillator Shocks in MADIT II: Frequency, Mechanisms, Predictors, and Survival Impact. J Am Coll Cardiol 51: 1357-1365 [Abstract] [Full Text]  
• Reddy, V. Y., Reynolds, M. R., Neuzil, P., Richardson, A. W., Taborsky, M., Jongnarangsin, K., Kralovec, S., Sediva, L., Ruskin, J. N., Josephson, M. E. (2007). Prophylactic Catheter Ablation for the Prevention of Defibrillator Therapy. NEJM 357: 2657-2665 [Abstract] [Full Text]  
• Estes, N.A. M. III (2007). Ablation after ICD Implantation -- Bridging the Gap between Promise and Practice. NEJM 357: 2717-2719 [Full Text]  
• Almendral, J., Josephson, M. E. (2007). All Patients With Hemodynamically Tolerated Postinfarction Ventricular Tachycardia Do Not Require an Implantable Cardioverter-Defibrillator. Circulation 116: 1204-1212 [Full Text]  
• Schoenfeld, M. H. (2007). Contemporary Pacemaker and Defibrillator Device Therapy: Challenges Confronting the General Cardiologist. Circulation 115: 638-653 [Full Text]  
• Ferreira-Gonzalez, I., Dos-Subira, L., Guyatt, G. H. (2007). Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. Eur Heart J 28: 469-477 [Abstract] [Full Text]  
• Gehi, A. K., Mehta, D., Gomes, J. A. (2006). Evaluation and Management of Patients After Implantable Cardioverter-Defibrillator Shock. JAMA 296: 2839-2847 [Abstract] [Full Text]  
• Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., Stevenson, W. (2006). The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions. Circulation 114: 2871-2891 [Full Text]  
• Haverkamp, W. (2006). Electrical storm: still a cryptogenic phenomenon?. Eur Heart J 27: 2921-2922 [Full Text]  
• Developed in Collaboration With the European Heart, , Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., Priori, S. G., Quinones, M. A., Roden, D. M., Silka, M. J., Tracy, C., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Antman, E. M., Anderson, J. L., Hunt, S. A., Halperin, J. L., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48: 1064-1108 [Full Text]  
• Developed in Collaboration With the European Heart, , Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., Priori, S. G., Quinones, M. A., Roden, D. M., Silka, M. J., Tracy, C., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Antman, E. M., Anderson, J. L., Hunt, S. A., Halperin, J. L., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48: e247-e346 [Full Text]  
• Zipes, D. P., Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., Priori, S. G., Quinones, M. A., Roden, D. M., Silka, M. J., Tracy, C., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L., ACC/AHA (Practice Guidelines) Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Antman, E. M., Anderson, J. L., Hunt, S. A., Halperin, J. L., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.. Eur Heart J 27: 2099-2140 [Full Text]  
• Writing Committee Members, , Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., Priori, S. G., Quinones, M. A., Roden, D. M., Silka, M. J., Tracy, C., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L., ACC/AHA Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Antman, E. M., Anderson, J. L., Hunt, S. A., Halperin, J. L., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8: 746-837 [Full Text]  
• Klein, G., Lissel, C., Fuchs, A.-C., Gardiwal, A., Oswald, H., deSousa, M., Pichlmaier, A. M., Lichtinghagen, R., Geerlings, H., Lippolt, P., Niehaus, M., Drexler, H., Korte, T. (2006). Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.. Europace 8: 618-624 [Abstract] [Full Text]  
• Brouwer, I. A., Zock, P. L., Camm, A. J., Bocker, D., Hauer, R. N. W., Wever, E. F. D., Dullemeijer, C., Ronden, J. E., Katan, M. B., Lubinski, A., Buschler, H., Schouten, E. G., for the SOFA Study Group, (2006). Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial.. JAMA 295: 2613-2619 [Abstract] [Full Text]  
• Connolly, S. J., Dorian, P., Roberts, R. S., Gent, M., Bailin, S., Fain, E. S., Thorpe, K., Champagne, J., Talajic, M., Coutu, B., Gronefeld, G. C., Hohnloser, S. H., for the Optimal Pharmacological Therapy in Cardiov, (2006). Comparison of {beta}-Blockers, Amiodarone Plus {beta}-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators: The OPTIC Study: A Randomized Trial. JAMA 295: 165-171 [Abstract] [Full Text]  
• Page, R. L. (2006). Antiarrhythmic Drugs for All Patients With an ICD?. JAMA 295: 211-213 [Full Text]  
• Patwala, A Y, Wright, D J (2005). Device based treatment of heart failure. Postgrad. Med. J. 81: 286-291 [Abstract] [Full Text]  
• Hanna, I. R., Langberg, J. J. (2004). The Shocking Story of Azimilide. Circulation 110: 3624-3626 [Full Text]  
• Dorian, P., Borggrefe, M., Al-Khalidi, H. R., Hohnloser, S. H., Brum, J. M., Tatla, D. S., Brachmann, J., Myerburg, R. J., Cannom, D. S., van der Laan, M., Holroyde, M. J., Singer, I., Pratt, C. M., on Behalf of the SHock Inhibition Evaluation with, (2004). Placebo-Controlled, Randomized Clinical Trial of Azimilide for Prevention of Ventricular Tachyarrhythmias in Patients With an Implantable Cardioverter Defibrillator. Circulation 110: 3646-3654 [Abstract] [Full Text]  
• Singer, I., Al-Khalidi, H., Niazi, I., Tchou, P., Simmons, T., Henthorn, R., Holroyde, M., Brum, J. (2004). Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 43: 39-43 [Abstract] [Full Text]  
• Curtis, A. B. (2004). Filling the need for new antiarrhythmic drugs to prevent shocks from implantable cardioverter defibrillators. J Am Coll Cardiol 43: 44-46 [Full Text]  
• Quesada, A., Almendral, J.ús, Arribas, F., Ricci, R., Wolpert, C., Adragao, P., Cobo, E., Navarro, X., on behalf DATAS investigators, (2004). The DATAS rationale and design: a controlled, randomized trial to assess the clinical benefit of dual chamber (DDED) defibrillator. Europace 6: 142-150 [Abstract] [Full Text]  
• DiMarco, J. P. (2003). Implantable Cardioverter-Defibrillators. NEJM 349: 1836-1847 [Full Text]  
• Anderson, K. P. (2003). Lipid-lowering therapy for prevention of ventricular tachyarrhythmias. J Am Coll Cardiol 42: 88-92 [Full Text]  
• Stevenson, W. G., Soejima, K. (2003). Inside or out? Another option for incessant ventricular tachycardia. J Am Coll Cardiol 41: 2044-2045 [Full Text]  
• Al-Khatib, S. M., LaPointe, N. M. A., Kramer, J. M., Califf, R. M. (2003). What Clinicians Should Know About the QT Interval. JAMA 289: 2120-2127 [Abstract] [Full Text]  
• Forlani, S., De Paulis, R., de Notaris, S., Nardi, P., Tomai, F., Proietti, I., Ghini, A. S., Chiariello, L. (2002). Combination of sotalol and magnesium prevents atrial fibrillation after coronary artery bypass grafting. Ann. Thorac. Surg. 74: 720-726 [Abstract] [Full Text]  
• Stein, K. M., Euler, D. E., Mehra, R., Seidl, K., Slotwiner, D. J., Mittal, S., Markowitz, S. M., Lerman, B. B., Jewel AF Worldwide Investigators, (2002). Do atrial tachyarrhythmias beget ventricular tachyarrhythmias in defibrillator recipients?. J Am Coll Cardiol 40: 335-340 [Abstract] [Full Text]  
• Schron, E. B., Exner, D. V., Yao, Q., Jenkins, L. S., Steinberg, J. S., Cook, J. R., Kutalek, S. P., Friedman, P. L., Bubien, R. S., Page, R. L., Powell, J. (2002). Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators Trial: Impact of Therapy and Influence of Adverse Symptoms and Defibrillator Shocks. Circulation 105: 589-594 [Abstract] [Full Text]  
• Saoudi, N., Rinaldi, J.P., Yaici, K., Bergonzi, M. (2001). Dofetilide: what role in the treatment of ventricular tachyarrhythmias?. Eur Heart J 22: 2141-2143  
• Boriani, G., Lubinski, A., Capucci, A., Niederle, P., Kornacewicz-Jack, Z., Wnuk-Wojnar, A.M., Borggrefe, M., Brachmann, J., Biffi, M., Butrous, G.S., on behalf of Ventricular Arrhythmias Dofetilide In, (2001). A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J 22: 2180-2191 [Abstract]  
• Chan, K. B.Y., Man-Son-Hing, M., Molnar, F. J., Laupacis, A. (2001). How well is the clinical importance of study results reported? An assessment of randomized controlled trials. CMAJ 165: 1197-1202 [Abstract] [Full Text]  
• Connelly, D. T (2001). ELECTROPHYSIOLOGY: Implantable cardioverter-defibrillators. Heart 86: 221-226 [Full Text]  
• Freedberg, N. A., Hill, J. N., Fogel, R. I., Prystowsky, E. N., the CARE Group, (2001). Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: Implications for antiarrhythmic therapy and driving restrictions. J Am Coll Cardiol 37: 1910-1915 [Abstract] [Full Text]  
• Mazeika, P (2001). Aborted sudden cardiac death: a clinical perspective. Postgrad. Med. J. 77: 363-370 [Abstract] [Full Text]  
• Gronefeld, G., Hohnloser, S. H (2001). What do implantable cardioverter/defibrillators teach us about the mechanisms of sudden cardiac death?. Cardiovasc Res 50: 232-241 [Abstract] [Full Text]  
• Singh, B. N., Sarma, J. S. M. (2001). Mechanisms of Action of Antiarrhythmic Drugs Relative to the Origin and Perpetuation of Cardiac Arrhythmias. J CARDIOVASC PHARMACOL THER 6: 69-87  
• Efimov, I. R. (2000). A Shocking Experience : Ionic Modulation of Virtual Electrodes in Defibrillation. Circ. Res. 87: 429-430 [Full Text]  
• Saksena, S. (2000). Implantable defibrillators in the third millennium: increasingly relegated to a standby role?. J Am Coll Cardiol 36: 828-831 [Full Text]  
• Rosen, M. R. (1999). Leaky Dikes and Fibrillating Swine. Circulation 100: 1942-1944 [Full Text]  
• Pratt, C.M, Camm, A.J, Bigger, J.T Jr, Breithardt, G, Campbell, R.W.F, Epstein, A.E, Kappenberger, L.J, Kuck, K.-H, Pocock, S, Saksena, S, Waldo, A.L (1999). Evaluation of antiarrhythmic drug efficacy in patients with an ICD. Unlimited potential or replete with complexity and problems?. Eur Heart J 20: 1538-1552 [Abstract]  
• Podrid, P. J. (1999). Redefining the Role of Antiarrhythmic Drugs. NEJM 340: 1910-1912 [Full Text]